Next Generation Sequencing is a powerful emerging method for detecting residual acute myeloid leukemia (AML) after treatment. However, current methods produce an abundance of sequencing errors which obscure low-frequency leukemia-defining mutations.

The TwinStrand Duplex Sequencing™ AML MRD assay is orders of magnitude more sensitive and specific than other NGS based MRD assays, offering unprecedented opportunities for clinical research and drug development.

**Duplex Sequencing AML MRD**

>100-fold higher resolution than other error-corrected NGS methods, revealing more clinically significant mutations

The 29 gene, 58kb panel encompasses loci mutated in >92% of adult AML patients

Assay enables sub-1/100,000 limit of detection anywhere in target region

**Duplex Sequencing MRD Technical Performance**

The TwinStrand Duplex Sequencing AML MRD assay was used to sequence a serially-diluted mixture of AML mutation-containing DNA to a Duplex depth >1,000,000x. Target clones were identified to levels <1/100,000 with 100% sensitivity and specificity.
Panel Overview

The AML panel encompasses the whole coding region or hotspots in 29 genes recurrently mutated in AML, MDS (myelodysplastic syndrome), and CHIP (clonal hematopoiesis).